Chugai Pharmaceutical Co Ltd
Company Profile
Business description
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
Contact
2-1-1 Muromachi, Nihonbashi
12th Floor, Nihonbashi Mitsui Tower
Chuo-ku
Tokyo103-8324
JPNT: +81 332816611
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
7,872
Stocks News & Analysis
stocks
Australia’s oldest REIT undervalued
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
stocks
Are negative AI narratives holding this ASX share back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.40 | 71.60 | -0.80% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 70,474.96 | 412.64 | 0.59% |
| NZX 50 Index | 13,606.90 | 3.60 | -0.03% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,722.90 | 71.70 | -0.82% |
| SSE Composite Index | 4,094.40 | 20.50 | 0.50% |